Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.

Cancer - 15 Jul 2017

Silver Richard T, Barel Ariella C, Lascu Elena, Ritchie Ellen K, Roboz Gail J, Christos Paul J, Orazi Attilio, Hassane Duane C, Tam Wayne, Cross Nicholas C P

Abstract excerpt

BACKGROUND: Although recombinant interferon-α (rIFNα) effectively treats patients with early myelofibrosis, the effect of driver and high molecular risk (HMR) mutations has not been considered. In this phase 2 study, for the first time, the authors correlate response to rIFNα treatment with driver and HMR mutations. METHODS: Patients were diagnosed using World Health Organization or International Working Group...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calreticulin
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon alpha-2

Share to Janus Kinase 2

Share to Janus Kinases

Share to Polyethylene Glycols

Share to Primary Myelofibrosis

Share to Receptors, Thrombopoietin

Source

Identifiers

PMID: 28518222
DOI: 10.1002/cncr.30679

Genes

ASXL1
CALR
MPL
SRSF2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.PMID 28518222Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses.Semantic proximity Read ↗

Momelotinib therapy for myelofibrosis: a 7-year follow-up.Semantic proximity Read ↗

ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial.Semantic proximity Read ↗

Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study.Semantic proximity Read ↗

ASXL1 Mutations with Serum EPO Levels Predict a Poor Response to Darbepoetin Alfa in Lower-Risk MDS: W-JHS MDS01 TrialSemantic proximity Read ↗

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.Semantic proximity Read ↗

Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival.Semantic proximity Read ↗

Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response.Semantic proximity Read ↗

Is there a role for the use of IFN-α in primary myelofibrosis?Semantic proximity Read ↗

Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Semantic proximity Read ↗

Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.